LOCOREGIONALLY RECURRENT HORMONE-RECEPTOR POSITIVE BREAST CANCER
Clinical trials for LOCOREGIONALLY RECURRENT HORMONE-RECEPTOR POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new LOCOREGIONALLY RECURRENT HORMONE-RECEPTOR POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for LOCOREGIONALLY RECURRENT HORMONE-RECEPTOR POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted therapy duo enters human trials for advanced breast cancer
Disease control Recruiting nowThis early-phase study tests two related drugs: one to help see tumors on scans (68Ga-R11228) and another to deliver radiation directly to cancer cells (177Lu-R11228). It is for people with advanced hormone-receptor positive breast cancer that has spread or come back. The main go…
Matched conditions: LOCOREGIONALLY RECURRENT HORMONE-RECEPTOR POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Radionetics Oncology • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
Radioactive tracer could spot hidden breast cancer tumors
Diagnosis Recruiting nowThis early-phase trial is testing a new radioactive imaging agent called 68Ga-R10602 in 36 people with hormone receptor-positive breast cancer that has come back or spread. The agent is designed to light up tumors on PET/CT scans. The main goals are to check safety and see how we…
Matched conditions: LOCOREGIONALLY RECURRENT HORMONE-RECEPTOR POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Radionetics Oncology • Aim: Diagnosis
Last updated Jun 23, 2026 11:54 UTC